Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VOR vs NKTR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VOR Captures Overall Composite Edge (57.8 HOLD vs 61.1 BUY), While NKTR Leads 3–2 on Growth & Valuation Pillars

VOR Overall Winner 6-Pillar Tally: VOR 2 – 3 NKTR (1 Tie) Matrix Metrics: VOR 4 – 5 NKTR

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Nektar Therapeutics (NKTR) on higher Unified Composite conviction (57.8/100 HOLD vs. 61.1/100 BUY) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NKTR wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $18.97 (N/M Forward P/E, 0.0% operating margin) versus NKTR at $36.44 (34.0x Forward P/E, -303.6% operating margin).

  • Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD), VOR captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -303.6% operating margin) and revenue trajectory (+0.0% vs. -20.4% YoY).
  • Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VOR vs NKTR
VOR NASDAQ Head-to-Head Winner
Vor Biopharma Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$18.97
-2.32% 1D
Market Cap $1.2B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.90β · 61% Vol
Unified Composite Score
57.8 / 100 HOLD
Tech 50.0 Fund 55.0 Flow 66.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.4 · SMA20: $19.48 · SMA50: $19.87
NKTR NASDAQ
Nektar Therapeutics
Pharmaceutical Preparations
$36.44
-2.23% 1D
Market Cap $1.3B
TTM Revenue $52M
Forward P/E 34.0x
Beta / 30D Vol 1.09β · 47% Vol
Unified Composite Score
61.1 / 100 BUY
Tech 47.0 Fund 58.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -23.3%), weak momentum, RSI 35
RSI-14: 35.3 · SMA20: $37.84 · SMA50: $47.72

6-Pillar Scorecard Institutional Category Breakdown (VOR 2 – 3 NKTR)

Columns: Metric · VOR · NKTR
1. Valuation Multiples NKTR
Forward P/E N/M 34.0x
Trailing P/E 0.1x 34.0x
PEG Ratio N/M 0.31x
EV / Revenue N/M 25.1x
2. Growth & Scale NKTR
Revenue Growth (YoY) +0.0% -20.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $52M
Market Cap $1.2B $1.3B
3. Profitability & Quality NKTR
Gross Margin N/A 100.0%
Operating Margin 0.0% -303.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -125.4% -37.9%
4. Balance Sheet & Cash Flow VOR
Cash Generation (TTM) -$1.63B -$234M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.04B Net Cash $39M Net Debt (0.09x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VOR
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 120.2% (6th %ile) 109.0% (11th %ile)
Put/Call OI Skew 2.03x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VOR (4) vs NKTR (5)
Institutional Metric VOR NKTR Criterion Row Edge
Market Capitalization
Scale
$1.2B $1.3B Larger Scale NKTR
Trailing P/E Ratio
Valuation
0.1x 34.0x Lower Multiple VOR
Forward P/E Ratio
Valuation
N/M 34.0x Lower Multiple NKTR
Revenue Growth (YoY)
Growth
+0.0% -20.4% Higher Growth VOR
Operating Margin (TTM)
Profitability
0.0% -303.6% Higher Margin VOR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-125.4% -37.9% Higher ROE NKTR
52-Week Range Position
Momentum
64% ($6–$26) 4% ($33–$109) Stronger Trend VOR
Beta / 30D Volatility
Risk Regime
1.90β · 61% Vol 1.09β · 47% Vol Lower Realized Risk NKTR
Unified Institutional Score
Composite Signal
57.8 / 100 (HOLD) 61.1 / 100 (BUY) Higher Composite NKTR
Trailing 12M Revenue (USD)
Operating Scale
N/A $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.31x PEG · 25.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$1.63B ($1.04B Net Cash) -$234M ($39M Net Debt (0.09x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VOR +3.37 pp
VOR: +5.21% · NKTR: +1.84%
3M Horizon VOR +32.01 pp
VOR: -18.51% · NKTR: -50.52%
6M Horizon VOR +81.0 pp
VOR: +34.25% · NKTR: -46.75%
1Y Horizon VOR +127.02 pp
VOR: +94.56% · NKTR: -32.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VOR vs NKTR. Trailing 12-month operating profitability (VOR 0.0% vs NKTR -303.6%) and valuation multiples (VOR N/M vs NKTR 34.0x Forward P/E) are benchmarked directly in Pillar 4 below.

VOR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-125.4% · N/M
NKTR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$52M
Gross Margin100.0%
Op. Margin-303.6%
ROE / Fwd P/E-37.9% · 34.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VOR CONSOLIDATION
52d in phase · OBV NEUTRAL
Current IV 120.2%
IV Percentile 6th %ile
Put/Call OI Skew 2.03x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NKTR BREAKDOWN
146d in phase · OBV NEUTRAL
Current IV 109.0%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NKTR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VOR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NKTR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -303.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VOR vs NKTR Key Questions & Quantitative Answers

As of Nov 16, 2026, Vor Biopharma Inc. (VOR) captures the overall head-to-head institutional edge over Nektar Therapeutics (NKTR) on higher Unified Composite conviction (57.8/100 HOLD vs. 61.1/100 BUY) after splitting the core matrix 4–5 (led by Balance Sheet & Cash Flow, Options & Positioning), while NKTR wins 3–2 across the 6-pillar growth and valuation breakdown. VOR trades at $18.97 (N/M Forward P/E, 0.0% operating margin) versus NKTR at $36.44 (34.0x Forward P/E, -303.6% operating margin). Composite vs. Pillar Nuance: While NKTR currently prints a higher short-term Unified Composite Score (61.1/100 BUY vs. VOR 57.8/100 HOLD), VOR captures the overall institutional head-to-head verdict (4–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -303.6% operating margin) and revenue trajectory (+0.0% vs. -20.4% YoY). Technical & Structure Timing Caution: VOR trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.4); meanwhile NKTR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 35.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NKTR leads the Growth & Scale pillar: VOR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NKTR at -20.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (100.0% gross margin, -303.6% operating margin). On trailing 12-month operating scale, VOR generates N/A in USD-normalized revenue versus $52M for NKTR. In operating R&D and SG&A reinvestment, VOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NKTR.

NKTR screens cheaper on headline valuation multiples. VOR trades at N/M Forward P/E, 0.1x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NKTR trades at 34.0x Forward P/E, 34.0x Trailing P/E, 0.31x PEG, and 25.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VOR (-125.4% ROE) versus NKTR (-37.9% ROE) capital efficiency.

In options market volatility and institutional positioning, VOR carries 120.2% implied volatility (6th %ile, Compressed (<25th %ile)), a 2.03x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.90β · 61% Vol realized risk). By comparison, NKTR carries 109.0% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.09β · 47% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.